Vetr And Evercore Put Jazz Pharmaceuticals At Buy

The Vetr crowd upgraded their ratingforJazz Pharmaceuticals plc JAZZ on Thursday, from 3 stars (Hold), issued two days ago, to 4 stars (Buy). At the time of the upgrade, crowd sentiment for the stock was mostly positive, with 83 percent of Vetr user ratings bullish.

Vetr's upgrade for the pharmaceutical company comes off of an analyst initiation from Evercore, who put the stock at Buy. The bullish initiation caused a brief spike of nearly 1.5 percent to $136.91 at today's open. The stock retreated back below the $136 mark to finish the day at 135.32.

Jazz's share price reached a six-month high of $138.66 earlier in the month. The company is expected to report Q4 earnings at the end of February.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for Jazz is up at $147.48, which is still below the average analyst target price of $180.29. Less than 2 percent of Vetr users are holding JAZZ in their watch lists.